CA Patent

CA2634149C — Novel hydrogen sulfate salt for use in the treatment of hyperproliferative diseases

Assigned to AstraZeneca AB · Expires 2013-08-13 · 13y expired

What this patent protects

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

USPTO Abstract

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: CA2634149C
Jurisdiction: CA
Classification: —
Expires: 2013-08-13
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.